

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

A)



B)

VH primers:

a	DP47baNco	GCG GCC CAG CAT GCC ATG GCC GAG GTG CAG CTG TTG GAG TCT GGG
b	CDR3for	GGT TCC CTG GCC CCA GTA GTC AAA MNN MNN MNN MNN TTT CGC ACA GTA ATA TAC G
c	VHpullth	GCG GCC CAG CAT GCC ATG GCC GAG
d	Jassm	CCC GCT ACC GCC ACT GGA CCC ATC GCC ACT CGA GAC GGT GAC CAG GGT TCC CTG GCC CCA GTA GTC

VL primers:

e	DPK22assm	GAT GGG TCC AGT GGC GGT AGC GGG GGC GCG TCG ACT GGC GAA ATT GTG TTG ACG CAG TCT CC
f	DPK3for	CAC CTT GGT CCC TTG GCC GAA CGT MNN CGG MNN MNN ACC MNN CTG CTG ACA GTA ATA CAC TGC
g	Jfornot	GAG TCA TTC TCG ACT TGC GGC CGC TTT GAT TTC CAC CTT GGT CCC TTG GCC GAA CG
h	pullth	GAT GGG TCC AGT GGC GGT AGC GGG

Figure 1




Figure 2A




Figure 2B



Figure 3





Figure 4



%ID/g time (h)	scFv (L19)							scFv (D1.3)	
	Kidney	Spleen	Lung	Liver	Brain	Blood	Tumor	Blood	Tumor
0.25	26.4 ± 4.7	5.4 ± 0.4	15.1 ± 5.1	5.7 ± 0.6	0.4 ± 0.04	14.4 ± 2.6	4.6 ± 1.0	12.7 ± 0.1	4.4 ± 0.4
1	19.2 ± 3.9	3.8 ± 0.3	9.8 ± 0.9	2.8 ± 0.3	0.3 ± 0.1	8.3 ± 0.9	6.9 ± 2.4	5.7 ± 0.7	3.6 ± 1.0
3	8.1 ± 1.6	2.0 ± 0.3	5.0 ± 1.4	1.7 ± 0.02	0.2 ± 0.01	4.3 ± 0.3	8.2 ± 4.2	—	—
5	4.2 ± 1.1	1.8 ± 0.2	3.5 ± 0.2	1.3 ± 0.3	0.1 ± 0.02	2.0 ± 1.6	7.7 ± 2.5	4.6 ± 1.2	2.6 ± 1.5
24	0.7 ± 0.1	0.4 ± 0.1	1.0 ± 0.1	0.2 ± 0.04	0.02 ± 0.01	0.4 ± 0.1	4.7 ± 0.6	1.1 ± 0.5	0.7 ± 0.4

Figure 5

VH

E V Q L L E S G G G	L V Q P G G S L R L	S C A A S G F T F S
S F S M S W V R Q A	P G K G L E W V S S	I S G S S G T T Y Y
A D S V K G R F T I	S R D N S K N T L Y	L Q M N S L R A E D
T A V Y Y C A K P F	P Y F D Y W G Q G T	L V T V S S

linker

G D G S S G G S G G A S T G

VL

E I V L T Q S P G T	L S L S P G E R A T	L S C R A S Q S V S
S S Y L A W Y Q Q K	P G Q A P R L L I Y	Y A S S R A T G I P
D R F S G S G S G T	D F T L T I S R L E	P E D F A V Y Y C Q
Q T G R I P P T F G	Q G T K V E I K	

Figure 6: Amino acid sequence of antibody L19

A high-contrast, black and white photograph of a person's face, heavily shadowed and distorted, possibly due to a severe condition or injury. The image is grainy and appears to be a photocopy or a scan of a photograph. The face is mostly obscured by deep shadows, with only the eyes and parts of the nose and mouth visible. The overall effect is one of horror and mystery.



Figure 7

001220 23021500



Figure 8

Micrograph (a) shows a cross-section of a polymer blend. A dark, irregular phase is visible on the left side, while the right side is a lighter, textured phase. A scale bar is present in the bottom left corner.




FIG. 9

FIG. 10

Figure 1 consists of 12 electron micrographs arranged in a 4x3 grid, labeled (a) through (l). The images are organized into two columns: the left column (a, c, e, g, i, k) shows control eyes, and the right column (b, d, f, h, j, l) shows eyes treated with 10^{-5} M retA. The top row (a, b) shows the vitreal surface of the retina, with a label 'P' indicating the pigmented epithelium. The middle row (c, d) shows the pigmented epithelium, with arrows pointing to microvilli. The bottom row (e, f) shows the vitreal surface of the retina. The images show the developing chick eye at 10 days of incubation, with the vitreal surface of the retina and the pigmented epithelium visible. The retA treatment appears to affect the morphology of the microvilli on the pigmented epithelium.

FIG. 11




FIG. 12

FIGURE 13







FIGURE 14



00000 2502T560

FIGURE 15

Radioimmunotherapy with anti-angiogenesis antibodies



vessels = 0.5 - 5%
of total tumour mass





FIGURE 16





FIGURE 17a

^1H -NMR spectrum of 3-(trimethylstannyl)-benzoic acid in CDCl_3



$(\text{CH}_3)_3$

Current Data Parameters
NAME test_0004
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 990804
Time 11.19
INSTRUM drxg00
PROBHD 5 mm TXI 13C
PULPROG zgpg. eth
TD 8192
SOLVENT CDCl3
NS 16
DS 2
SWH 9615.385 Hz
FLORES 1.173753 Hz
AQ 0.4260340 sec
RG 800
DM 52.000 usec
DE 8.00 usec
TE 294.0 K
D1 1.00000000 sec

===== CHANNEL f1 =====
NUC1 ^1H
P1 8.00 usec
PL1 0.00 dB
PL9 120.00 dB
SF01 600.1328114 MHz

===== GRADIENT CHANNEL =====
GPNAM1 sine.32
GPX1 0.00 %
GPY1 0.00 %
GPZ1 50.00 %
PZ1 1000.00 usec

F2 - Processing parameters
SI 4096
SF 600.1300239 MHz
WDW OSINE
SSB 3
LB 0.00 Hz
GB 0
PC 1.00

1D NMR plot parameters
CX 20.00 cm
FIP 8.811 ppm
F1 5287.97 Hz
F2 -204.86 Hz
PPMCH 0.45764 ppm/cm
W/FM 274.64160 Hz/cm






FIGURE 17b

^1H -NMR spectrum of 3-(trimethylstannyl)-benzoic acid in CDCl_3



Current Data Parameters
NAME test_0004
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 990004
Time 11.19
INSTRUM drx600
PROBHD 5 mm TXI 13C
PULPROG zgpg. eth
TD 8192
SOLVENT CDCl_3
NS 16
DS 2
SMH 9615.385 Hz
FIDRES 1.173753 Hz
AQ 0.4260340 sec
RG 800
DM 52.000 usec
DE 8.00 usec
TE 294.0 K
D1 1.00000000 sec

CHANNEL f1
NUC1 ^1H
P1 8.00 usec
PL1 0.00 dB
PL9 120.00 dB
SF01 600.1320114 MHz


GRADIENT CHANNEL
GPNAM1 sine_32
GPX1 0.00 X
GPY1 0.00 X
GPZ1 50.00 X
PZ1 1000.00 usec

F2 - Processing parameters
SI 4096
SF 600.1300239 MHz
WDW OSINE
SSD 3
LB 0.00 Hz
GB 0
PC 1.00

1D NMR plot parameters
CX 20.00 cm
FIP 8.513 ppm
F1 5108.78 Hz
F2P 6.977 ppm
F2 4187.17 Hz
PPMCK 0.07678 ppm/cm

FIGURE 18a

^1H -NMR spectrum of N-succinimidy1-3-(trimethylstannyl)-benzoate in CDCl_3



m-MeATE

$\text{CO-CH}_2\text{-CH}_2\text{-CO}$

$(\text{CH}_3)_3$

C_2
 C_4
 C_5
 CHCl_3

9

4

9

8

7

6

5

4

3

2

1

ppm

FIGURE 18b

^1H -NMR spectrum of N-succinimidy-3-(trimethylstannyl)-benzoate in CDCl_3




FIGURE 19
EI-MS of N-succinimidyl-3-(trimethylstannyl)-benzoate in CDCl₃

